Shares of Gritstone Oncology Inc (NASDAQ: GRTS) climbed 3.7% in after-market trading to $9.8 at the last check. During the regular trading on Tuesday, Gritstone stock closed the session at $9.45, decreasing -2.38 percent, or -$0.23.
Over a year, the GRTS stock rose 24.18%, and within the last week, the stock moved up 9.88%. The GRTS stock has surged in the absence of any relevant news, but a recent update is likely to serve as a better guide.
Gritstone is a clinical-stage biotech that develops immunotherapies against multiple types of cancer as well as infectious diseases. A key component of the GRTS product development process is the integration of two key pillars:
Firstly: A proprietary machine learning-based platform, Gritstone EDGETM, which predicts antigens on the surface of cells, such as those derived from tumors, which can be scanned by the immune system.
Secondly: Another advantage of these antigens is that they can be employed by their manufacturers to create potent immunotherapies aimed at specifically attacking and destroying disease-causing cells.
In a Phase 1 study under GRTS’s “CORAL” program, Gritstone last month announced that it has dosed the first patient with its candidate vaccine COVID-19.
- Through the GRTS study, it was hoped to find out if using its self-amplifying mRNA (SAM) and adenoviral vectors with SARS-CoV-2 virus antigens would be immunogenic and safe.
- The three antigens under study by GRTS include both Spike Antigen and other antigens not included in current licensed vaccines.
- Infectious Diseases Clinical Research Consortium (IDCRC) funded the Phase 1 trial of Gritstone (GRTS) by the National Institute of Allergy and Infectious Diseases (NIAID).